# Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

> **NCT03143998** · PHASE4 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-5172A

## Key facts

- **NCT ID:** NCT03143998
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-02-12
- **Primary completion:** 2019-01-12
- **Final completion:** 2019-01-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03143998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03143998, "Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03143998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*